Immunotherapy News and Research

Latest Immunotherapy News and Research

Bioniche Life Sciences update on Phase III clinical program for evaluating Urocidin

Bioniche Life Sciences Inc., a research-based, technology-driven Canadian biopharmaceutical company, today provided an update on its Phase III clinical program evaluating Urocidin(TM) in the treatment of bladder cancer.

24 Aug 2009

Official launch of the FocusUP website announced

HST Global, Inc. today announced the official launch of the FocusUP® Website located at www.focusup.com FocusUP is the cognitive function product endorsed and recommended by Dr. Kyl Smith under a Joint Venture with Dalham, LLC (an affiliate company of The Health Network, Inc.).

20 Aug 2009

Opexa Therapeutics reports Q2 2009 financials

Opexa Therapeutics, Inc. (NASDAQ:OPXA), a company developing a novel T-cell therapy for multiple sclerosis (MS), today reported financial results for the quarter ended June 30, 2009, and provided details on further developments.

13 Aug 2009

Potential new treatment for drug resistant brain tumors

Dr. Karen Newell, Ph. D., the lead researcher for bio technology company Viral Genetics (Pink Sheets: VRAL), will address the 4th Annual Aspen Symposium on Brain Tumor Immuno- and Stem Cell Therapy. Her presentation will highlight the potential for combining chemotherapy with compounds that interfere with the ability of brain tumor cells to generate the energy needed to repair chemotherapy induced DNA damage.

12 Aug 2009

Dendreon signs lease for new manufacturing facility in Union City, Ga

Dendreon Corporation (Nasdaq: DNDN) today announced it has signed a lease agreement with Majestic Realty Co. to build a 160,000 square-foot manufacturing facility in Union City, Ga., where it expects to manufacture PROVENGE(R) (sipuleucel-T) for patients with advanced prostate cancer. The state of Georgia will be hosting a ribbon-cutting ceremony on September 30.

10 Aug 2009

Cancer Therapy & Research Center (CTRC) retains status as NCI-designated cancer center

The National Cancer Institute, the nation’s top cancer research organization, has renewed the Cancer Therapy & Research Center (CTRC) at The University of Texas Health Science Center at San Antonio as one of its NCI-designated Cancer Centers for three years. The distinction comes with $5.4 million in new federal funding through 2012 to sustain and grow the cancer center’s rapidly expanding research programs, now consisting of 140 scientists at work on a multitude of cancer projects.

4 Aug 2009

Cancer immunotherapy can use small numbers of ‘stem-like’ immune cells to destroy large tumors in mice

A new approach to stimulating immune cells enhances their anticancer activity, resulting in a powerful anti-tumor response in mice, according to a study by researchers at the National Cancer Institute, a part of the National Institutes of Health. This work represents an important advance in the development of immunotherapy for cancer and appears online June 14, 2009 in Nature Medicine.

15 Jun 2009

Interleukin-2 shows promise against advanced melanoma

A vaccine for one of the most lethal cancers, advanced melanoma, has shown improved response rates and progression-free survival for patients when combined with the immunotherapy drug, Interleukin-2, according to researchers from The University of Texas M. D. Anderson Cancer Center.

1 Jun 2009

Experimental therapy uses immune system to boost cure rate in neuroblastoma

A multicenter research team has announced encouraging results for an experimental therapy using elements of the body's immune system to improve cure rates for children with neuroblastoma, a challenging cancer of the nervous system.

27 May 2009

Arthritis drug Abatacept may be effective in fighting the flu

Researchers at the University of Maryland School of Medicine have found that an approved drug for treating rheumatoid arthritis reduces severe illness and death in mice exposed to the Influenza A virus. Their findings suggest that tempering the response of the body's immune system to influenza infection may alleviate some of the more severe symptoms and even reduce mortality from this virus.

26 May 2009

Bioniche updates on phase III clinical trial with Urocidin in non-muscle-invasive bladder cancer

Bioniche Life Sciences Inc. has provided an update on its Phase III clinical program evaluating Urocidin(TM) in the treatment of bladder cancer. On March 31st, the Company announced that recruitment had been completed in its initial Phase III registration trial evaluating Urocidin in the treatment of non-muscle-invasive bladder cancer that is refractory (unresponsive) to the current standard immunotherapy - Bacillus Calmette-Guérin (BCG).

25 May 2009

HER2/neu protein predicts development of invasive breast cancer in women with ductal carcinoma in situ

Women with ductal carcinoma in situ (DCIS) who exhibit an overexpression of the protein HER2/neu have a six-fold increase in risk of invasive breast cancer, according to a new study from the University of Pennsylvania School of Medicine.

22 May 2009

Disruption of immune-system pathway key step in cancer progression

Human immune cells communicate constantly with one another as they coordinate to fight off infection and other threats.

18 May 2009

New therapy improves chances of living disease-free with neuroblastoma

A phase III study has shown that adding an antibody-based therapy that harnesses the body's immune system resulted in a 20 percent increase in the number of children living disease-free for at least two years with neuroblastoma.

15 May 2009

Alzheimer's vaccine slows progression of inclusion body myositis

A potential vaccine for Alzheimer's disease also has been shown in mice to slow the weakening of muscles associated with inclusion body myositis, a disorder that affects the elderly.

13 May 2009

Discovery of process that controls T cell growth

Identifying one of the processes that plays a role in naïve and memory T-cells' growth and production could one day lead to better vaccines and possibly more effective cancer immunotherapy, said researchers at Baylor College of Medicine and Texas Children's Hospital in a report that appears in the current edition of Nature Immunology.

3 May 2009

Sublingual immunotherapy for inhalant allergies deserves deeper consideration

Sublingual immunotherapy for the treatment of allergy symptoms caused by a wide variety of environmental inhalants has been effectively used in Europe.

30 Apr 2009

Experimental immunotherapy significantly prolongs survival in men with advanced prostate cancer

Sipuleucel-T (Provenge), an experimental immunotherapy improved survival in men with metastatic disease, according to new results to be presented April 28 at the American Urological Association (AUA) Annual Scientific Meeting in Chicago.

29 Apr 2009

New cancer centre launched in Southampton

Southampton joins a unique chain of Cancer Research UK Centres that are being launched across the UK.

29 Apr 2009

Scientists improve immune response to cancer

A team of scientists at The Campbell Family Institute for Breast Cancer Research (CFIBCR) at Princess Margaret Hospital and international collaborators have discovered how to trigger an improved immune response to cancer that could be included in new clinical trials that use a patient's own cells to destroy tumours.

26 Apr 2009